Skeletal muscle mitochondrial DNA content and aerobic metabolism in patients with antiretroviral therapy-associated lipoatrophy

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 7, 2010, Pages 1497-1504

  Sutinen, Jussi ^a   Laaksonen, Marko S ^b,c   Walker, Ulrich A ^d,e   Setzer, Bernhard ^d   Kemppainen, Jukka ^b,f   Nuutila, Pirjo ^b,f   Yki Järvinen, Hannele ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b TURKU PET CENTRE   (Finland)

^c MID SWEDEN UNIVERSITY   (Sweden)

^d UNIVERSITY OF FREIBURG   (Germany)

^e Felix Platter Spital   (Switzerland)

^f UNIVERSITY OF TURKU   (Finland)

Author keywords

Lipodystrophy; Muscle biopsy; Positron emission tomography

Indexed keywords

ANTIRETROVIRUS AGENT; MITOCHONDRIAL DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ADIPOSE TISSUE; ADULT; AEROBIC METABOLISM; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA CONTENT; EXERCISE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTATE BLOOD LEVEL; LEG MUSCLE; LIPOATROPHY; MALE; MUSCLE BLOOD FLOW; MUSCLE MASS; MUSCLE PERFUSION; OXYGEN CONSUMPTION; QUADRICEPS FEMORIS MUSCLE; SKELETAL MUSCLE; SUBCUTANEOUS FAT; VIRUS LOAD; ANAEROBIC GROWTH; BLOOD FLOW; COMPARATIVE STUDY; COMPLICATION; CROSS-SECTIONAL STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HIV INFECTIONS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; ANAEROBIOSIS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; DNA, MITOCHONDRIAL; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; QUADRICEPS MUSCLE; REGIONAL BLOOD FLOW;

EID: 77954203606     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq138     Document Type: Article

References (49)

1. Bhaskaran K, Hamouda O, Sannes M et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300:51-9.
2. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352: 48-62.
3. Brinkman K, Smeitink JA, Romijn JA et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112-5.
4. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22: 685-708.
5. Shikuma CM, Hu N, Milne C et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001; 15: 1801-9.
6. Walker UA, Bickel M, Lutke Volksbeck SI et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002; 29: 117-21.
7. Rabing Christensen E, Stegger M, Jensen-Fangel S et al. Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: a randomized, double-blind, placebo-controlled pilot study. Clin Infect Dis 2004; 39: 1371-9.
8. Gerschenson M, Shiramizu B, LiButti DE et al. Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals. Antivir Ther 2005; 10 Suppl 2: M83-9.
9. van der Valk M, Casula M, Weverlingz GJ et al. Prevalenceoflipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1 infected patients randomly allocated to zidovudine or stavudine-based therapy. Antivir Ther 2004; 9:385-93.
10. Cossarizza A, Riva A, Pinti M et al. Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy. Antivir Ther 2003; 8: 315-21.
11. Arnaudo E, Dalakas M, Shanske S et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337: 508-10.
12. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors. Lancet 1997; 350: 1596.
13. Miller KD, Jones E, Yanovski JA et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351: 871-5.
14. Lebrecht D, Deveaud C, Beauvoit B et al. Uridine supplementation antagonizes zidovudine-induced mitochondrial myopathy and hyperlactatemia in mice. Arthritis Rheum 2008; 58: 318-26.
15. Desai VG, Lee T, Moland CL et al. Effect of short-term exposure to zidovudine (AZT) on the expression of mitochondria-related genes in skeletal muscle of neonatal mice. Mitochondrion 2009; 9: 9-16.
16. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-30.
17. Schambelan M, Benson CA, Carr A et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an international AIDS society-USA panel. J Acquir Immune Defic Syndr 2002; 31: 257-75.
18. Authier FJ, Chariot P, Gherardi RK. Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle Nerve 2005; 32: 247-60.
19. Nuutila P, Kalliokoski K. Use of positron emission tomography in the assessment of skeletal muscle and tendon metabolism and perfusion. Scand J Med Sci Sports 2000; 10: 346-50.
20. Sutinen J, Häkkinen AM, Westerbacka J et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy-a randomized double-blind placebo-controlled study. Antivir Ther 2003; 8: 199-207.
21. Laaksonen MS, Kalliokoski KK, Kyröläinen H et al. Skeletal muscle blood flow and flow heterogeneity during dynamic and isometric exercise in humans. Am J Physiol Heart Circ Physiol 2003; 284: H979-86.
22. Laaksonen MS, Kivelä R, Kyröläinen H et al. Effects of exhaustive stretch-shortening cycle exercise on muscle blood flow during exercise. Acta Physiol (Oxf) 2006; 186: 261-70.
23. Sipilä H, Clark JC, Peltola O et al. An automatic [15O]H2O production system for heart and brain studies. J Labelled Compd Rad 2001; 44: S1066-8.
24. Nuutila P, Raitakari M, Laine H et al. Role of blood flow in regulating insulin-stimulated glucose uptake in humans. Studies using bradykinin, [15O]water, and [18F]fluoro-deoxy-glucose and positron emission tomography. J Clin Invest 1996; 97: 1741-7.
25. Kalliokoski KK, Kemppainen J, Larmola K et al. Muscle blood flow and flow heterogeneity during exercise studied with positron emission tomography in humans. Eur J Appl Physiol 2000; 83: 395-401.
26. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-9.
27. Haugaard SB, Andersen O, Pedersen SB et al. Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased oxidative capacity in HIV-infected patients on highly active antiretroviral therapy. J Med Virol 2005; 77: 29-38.
28. Vittecoq D, Jardel C, Barthelemy C et al. Mitochondrialdamage associated with long-term antiretroviral treatment: associated alteration or causal disorder? J Acquir Immune Defic Syndr 2002; 31:299-308.
29. Zaera MG, Miro O, Pedrol E et al. Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. AIDS 2001; 15: 1643-51.
30. Mallon PW, Unemori P, Sedwell R et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005; 191: 1686-96.
31. Chapplain JM, Beillot J, Begue JM et al. Mitochondrial abnormalities in HIV-infected lipoatrophic patients treated with antiretroviral agents. J Acquir Immune Defic Syndr 2004; 37: 1477-88.
32. Roge BT, Calbet JA, Moller K et al. Skeletal muscle mitochondrial function and exercise capacity in HIV-infected patients with lipodystrophy and elevated p-lactate levels. AIDS 2002; 16: 973-82.
33. Miro O, Lopez S, Fernandez-Sola J et al. Short communication: HIV infection, antiretrovirals, and apoptosis: studies on skeletal muscle. AIDS Res Hum Retroviruses 2005; 21: 702-5.
34. Rabol R, Larsen S, Hojberg PM et al. Regional anatomic differences in skeletal muscle mitochondrial respiration in type 2 diabetes and obesity. J Clin Endocrinol Metab 2010; 95: 857-63.
35. Kosmiski LA, Ringham BM, Grunwald GK et al. Dual-energy X-ray absorptiometry modeling to explain the increased resting energy expenditure associated with the HIV lipoatrophy syndrome. Am J Clin Nutr 2009; 90: 1525-31.
36. Terry L, Sprinz E, Stein R et al. Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy. Med Sci Sports Exerc 2006; 38: 411-7.
37. Jones SP, Doran DA, Leatt PB et al. Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy. AIDS 2001; 15: 2049-51.
38. Thoni GJ, Fedou C, Brun JF et al. Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia. Diabetes Metab 2002; 28: 397-404.
39. Lindegaard B, Hansen T, Hvid T et al. The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy. J Clin Endocrinol Metab 2008; 93: 3860-9.
40. Mallon PW, Miller J, Cooper DA et al. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17: 971-9.
41. Nolan D, Hammond E, James I et al. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003; 8: 617-26.
42. Pozniak AL, Gallant JE, DeJesus E et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43: 535-40.
43. Carr A, Workman C, Smith DE et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288: 207-15.
44. McComsey GA, Paulsen DM, Lonergan JT et al. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005; 19: 15-23.
45. Hulgan T, Tebas P, Canter JA et al. Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J Infect Dis 2008; 197: 858-66.
46. Fleischman A, Johnsen S, Systrom DM et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab 2007; 292: E1666-73.
47. Bacchetti P, Grunfeld C, Heymsfield SB et al. Intermuscular adipose tissue is decreased in HIV infection. In: Abstracts of the Eleventh International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV, Philadelphia, PA, 2009. Antivir Ther 2009; 14 Suppl 2: A3. Abstract O01.
48. Goto Y. Clinical and molecular studies of mitochondrial disease. J Inherit Metab Dis 2001; 24: 181-8.
49. Mazat JP, Rossignol R, Malgat M et al. What do mitochondrial diseases teach us about normal mitochondrial functions...that we already knew: threshold expression of mitochondrial defects. Biochim Biophys Acta 2001; 1504: 20-30.